Conserved CTL Epitopes Within EBV Latent Membrane Protein 2: A Potential Target for CTL-Based Tumor Therapy

Journal of Immunology

Volumn 158, Issue 7, 1997, Pages 3325-3334

  Lee, Steven P ^a   Tierney, Rosemary J ^a   Thomas, Wendy A ^a   Brooks, Jill M ^a   Rickinson, Alan B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EPITOPE; HLA A ANTIGEN; HLA B ANTIGEN; MATRIX PROTEIN; PEPTIDE FRAGMENT;

ADOPTIVE IMMUNOTHERAPY; AMINO ACID SEQUENCE; ARTICLE; CARCINOMA; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; EPSTEIN BARR VIRUS; GENETIC POLYMORPHISM; GENETICS; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; MOLECULAR GENETICS; NASOPHARYNX TUMOR; NUCLEOTIDE SEQUENCE;

AMINO ACID SEQUENCE; CARCINOMA; CONSERVED SEQUENCE; EPITOPE MAPPING; EPITOPES; HERPESVIRUS 4, HUMAN; HLA-A ANTIGENS; HLA-B ANTIGENS; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MOLECULAR SEQUENCE DATA; NASOPHARYNGEAL NEOPLASMS; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 0031113988     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Lee, S. P. 1994. Control mechanisms of Epstein-Barr virus persistence. Semin. Virol. 5:281.
2. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr Virus. In Fields Virology, Vol. 2, 3rd Ed. B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven, Philadelphia, p. 2397.
3. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157.
4. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169.
5. Gavioli, R., P. O. de Campos-Lima, M. G. Kurilla, E. Kieff, G. Klein, and M. G. Masucci. 1992. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA4 and EBNA6 by HLA-A11-restricted cytotoxic T lymphocytes, implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc. Natl. Acad. Sci. USA 89:5862.
6. Papadopoulos, E. B., M. Ladanyi, D. Emanuel, S. Mackinnon, F. Boulad, M. H. Carabasi, H. Castro-Melaspina, B. H. Childs, A. P. Gillio, T. N. Small, J. W. Young, N. A. Kernan, and R. J. O'Reilly. 1994. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330:1185.
7. Rooney, C. M., C. A. Smith, C. Y. C. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epsiein-Barr virus-related lymphoproliferation. Lancet 345:9.
8. Heslop, H. E., C. Y. C. Ng, C. F. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney. 1996. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T-lymphocytes. Nat. Med. 2:551.
9. Gratama, J. W., M. M. Zutter, J. Minarovits, M. A. P. Oosterveer, E. D. Thomas, G. Klein, and I. Ernberg. 1991. Expression of Epstein-Barr virus growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int. J. Cancer 47:188.
10. Young, L., C. Alfieri, K. Hennessy, H. Evans, C. O'Hara, K. C. Anderson, J. Ritz, R. S. Shapiro, A. Rickinson, E. Kieff, and J. I. Cohen. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080.
11. Brooks, L., Q. Y. Yao, A. B. Rickinson, and L. S. Young. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:2689.
12. Busson, P., R. McCoy, R. Sadler, K. Gilligan, T. Tursz, and N. Raab-Traub. 1992. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J. Virol. 66:3257.
13. Deacon, E. M., G. Pallesen, G. Niedobitek, J. Crocker, L. Brooks, A. B. Rickinson, and L. S. Young. 1993. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177:339.
14. Herbst, H., F. Dallenbach, M. Hummel, G. Niedobitek, S. Pileri, N. Muller-Lantzsch, and H. Stein. 1991. Epstein-Barr virus latent membrane protein expression in Hodgkin and Recd-Sternberg cells. Proc. Natl. Acad. Sci. USA 88: 4766.
15. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen 1. Nature 375:685.
16. Krausa, P., M. Brywka, D. Savage, K. M. Hui, M. Bunce, J. L. F. Ngai, and D. L. T. Teo. 1995. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 45:223.
17. Lee, S. P., W. A. Thomas, R. J. Murray, F. Khanim, S. Kaur, L. S. Young, M. Rowe, M. Kurilla, and A. B. Rickinson. 1993. HLA-A2. 1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J. Virol. 67:7428.
18. Brooks, J. M., R. J. Murray, W. A. Thomas, M. G. Kurilla, and A. B. Rickinson. 1993. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J. Exp. Med. 178:879.
19. Miller, G., and M. Lipman. 1973. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc. Natl. Acad. Sci. USA 70:190.
20. Doumas, B. T. 1975. Standards for total serum protein assays: a collaborative study. Clin. Chem. 21:1159.
21. Bunce, M., C. M. O'Neill, M. C. N. M. Barnardo, P. Krausa, M. J. Browning, P. J. Morris, and K. I. Welsh. 1995. Phototyping: comprehensive DNA typing for HLA-A, HLA-B, HLA-C, DRB1, DRB3, DRB4, DRB5, and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46:355.
22. Burrows, S. R., A. Suhrbier, R. Khanna, and D. J. Moss. 1992. Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing. Immunology 76:174.
23. Baer, R., A. T. Bankier, M. D. Biggin, P. L. Deininger, P. J. Farrell, T. G. Gibson, G. Hatfull, G. S. Hudson, S. C. Satchwell, C. Seguin, P. S. Tuffnel, and B. G. Barrell. 1984. DNA sequence and expression of the B95.8 Epstein-Barr virus genome. Nature 310:207.
24. de Campos-Lima, P.-O., V. Levitsky, J. Brooks, S. P. Lee, L. F. Hu, A. B. Rickinson, and M. G. Masucci. 1994. T cell responses and virus evolution: loss of HLA-A11-restricted CTL epitopes in Epstein-Barr virus isolates from high A11-positive populations hy selective mutation of anchor residues. J. Exp. Med. 179:1297.
25. Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
26. Sudo, T., N. Kamikawaji, A. Kimura, Y. Date, C. J. Savoie, H. Nakashima, E. Furuichi, S. Kuhara, and T. Sasazuki. 1995. Differences in MHC class 1 self peptide repertoires among HLA-A2 subtypes. J. Immunol. 155:4749.
27. Imanishi, T., T. Akaza, A. Kimura, K. Tokunaga, and T. Gojobori. 1992. W15.1 reference tables. In HLA-1991. K. Tsuji, M. Aizawa, and T. Sasazuki, eds. Oxford University Press, Oxford, p. 1066.
28. Browning, M., and P. Krausa. 1996. Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol. Today 17:165.
29. Barouch, D., T. Friede, S. Stevanovic, L. Tussey, K. Smith, S. Rowland-Jones, V. Braud, A. McMichael, and H.-G. Rammensee. 1995. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J. Exp. Med. 182:1847.
30. Rivoltini, L., D. J. Loftus, K. Barracchini, F. Arienti, A. Mazzocchi, W. E. Biddison, M. L. Salgaller, E. Appella, G. Parmiani, and F. M. Marincola. 1996. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein 100 by HLA-A2 subtypes: implications for peptide-based immunotherapy. J. Immunol. 156:3882.
31. Fan, L., Z. Yao, A. Volgger, T. Ehret, J. Q. Yang, L. D. Xu, F. J. Yao, and E. D. Albert. 1996. Significant HLA-A*02 allelic variation revealed in Chinese and Caucasian populations. Hum. Immunol. 47:7.
32. Lee, T. D., T. M. Zhao, R. Mickey, Y. R Sun, G. Lee, C. X. Song, D. Z. Cheng, M. S. Zhou, S. Q. Ding, D. X. Cheng, F. J. Song, P. Y. Lee, J. B. An, and K. K. Mittal. 1988. The polymorphisms of HLA antigens in the Chinese. Tissue Antigens 32:188.
33. Hawkins, B. R. 1985. Evidence for the existence of HLA-A11 subgroups in Hong Kong Chinese. Tissue Antigens 25:83.
34. Kawaguchi, G., N. Kato, K. Kashiwase, S. Karaki, T. Kohsaka, T. Akaza, K. Kano, and M. Takiguchi. 1993. Structural analysis of HLA-B40 epitopes. Hum. Immunol. 36:193.
35. Schmidt, C., S. R. Burrows, T. B. Sculley, D. J. Moss, and I. S. Misko. 1991. Non-responsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc. Natl. Acad. Sci. USA 88:9478.
36. Burrows, S. R., J. Gardner, R. Khanna, T. Steward, D. J. Moss, S. Rodda, and A. Suhrbier. 1994. Five new cytotoxic T-cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J. Gen. Virol. 75:2489.
37. Hill, A. B., S. P. Lee, J. S. Haurum, N. Murray, Q. Y. Yao, M. Rowe, N. Signoret, A. B. Rickinson, and A. J. McMichael. 1995. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid lines against which they were raised. J. Exp. Med. 181:2221.
38. Chan, S. H., N. E. Day, N. Kunaratnam, K. B. Chia, and M. J. Simons. 1983. HLA and nasopharyngeal carcinoma in Chinese: a further study. Int. J. Cancer 32:171.
39. Lu, S.-J., N. E. Day, L. Degos, V. Lepage, P.-C. Wang, S.-H. Chan, M. Simons, B. McKnight, D. Easton, Y. Zeng, and G. de The. 1990. Linkage of nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 346:470.
40. Moss, D. J., S. H. Chan, S. R. Burrows, T. S. Chew, R. G. Kane, J. A. Staples, and N. Kunaratnam. 1983. Epstein-Barr virus T cell response in nasopharyngeal carcinoma patients. Int. J. Cancer 32:301.
41. Morgan, S. M., G. W. G. Wilkinson, E. Floettmann, N. Blake, and A. B. Rickinson. 1996. A recombinant adenovirus expressing an Epstein-Barr virus (EBV) target antigen can selectively reactivate rare components of EBV cytotoxic T-lymphocyte memory in vitro. J. Virol. 70:2394.
42. Frisan, T., J. Sjoberg, R. Dolcetti, M. Boiocchi, V. De Re, A. Carbone, C. Brautbar, S. Battat, P. Biberfeld, M. Eckman, A. Ost, B. Christensson, C. Sundstrom, M. Bjorkholm, P. Pisa, and M. G. Masucci. 1995. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86:1493.
43. Rowe, M., R. Khanna, C. A. Jacob, V. Argaet, A. Kelly, S. Powis, M. Belich, D. Croom-Carter, S. Lee, S. R. Burrows, J. Trowsdale, D. J. Moss, and A. B. Rickinson. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: co-ordinate up-regulation of peptide transporters and HLA class 1 antigen expression. Eur. J. Immunol. 25:1374.
44. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265.
45. Lee, S. P., W. A. Thomas, N. W. Blake, and A. B. Rickinson. 1996. Transporter (TAP)-independeni processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur. J. Immunol. 26:1875.
46. Khanna, R., S. R. Burrows, D. J. Moss, and S. L. Silins. 1996. Peptide transporter (Tap-1 and Tap-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2a: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J. Virol. 70:5357.